Teva’s 2022 Impact: A Closer Look

Each year, Teva publishes an Environmental, Social and Governance (ESG) Progress Report, which shares how we are managing topics important to our business and making a positive impact on people and the planet.

ESG is an integral part of our company, guided by a robust strategy, priority topics, dedicated governance structure and ambitious targets. Our focus on ESG supports us in creating long-term value and ensuring the sustainability of our company—allowing us to continue improving the lives of patients.

Our 2022 report offers a closer look at our latest progress, including how we’re delivering against our targets—reducing greenhouse gas emissions, increasing access to medicines, strengthening our culture of compliance and more. Some of our targets are also tied to sustainability-linked bonds, linking ESG with our financial strategy.

Here is a look at our impact last year.

We work to address climate change. Teva reduced scope 1 and 2 greenhouse gas (GHG) emissions by 24% (vs. 2019), putting us ahead of schedule to meet our 2025 target (25% reduction). Scope 1 and 2 GHG emissions are those generated through our operations and from the production of energy we buy, such as heating and cooling. In 2022, our targets to reduce GHG emissions were approved by the Science Based Targets initiative, indicating they are ambitious, grounded in science and aligned with global goals to combat climate change.

We get our medicines to people who otherwise would not have them. Teva launched 5 access to medicines programs as of 2022. Last year alone, these programs provided important treatments to more than 100,000 patients. Our partnerships span countries from Malawi to the US and range from treating children with cancer to helping people receive mental health care at free clinics. We are on track to reach our target of launching eight access to medicines programs by 2025.

We support patients and communities affected by humanitarian disasters and emergencies. Teva donated approximately 30.4M doses of essential medicines to Ukrainian people. This donation, worth $11.5M, was the largest of any pharmaceutical company at the time. We also created a solidarity fund for employees, by employees to support our colleagues and their families in Ukraine.

We operate with integrity and transparency. Teva trained nearly 100% of employees on compliance and ethics, helping Teva act in the best interest of about 200M patients each day. Throughout the year, our employees strengthen their understanding of ethics topics, such as anti-corruption, fair competition and data privacy. What we achieve is important, and how we achieve it is just as important.

We are proud of our progress, which is only possible because ESG is everyone’s business at Teva. Learn more in our latest report.